Formulation of niosomal gel for enhanced transdermal lopinavir delivery and its comparative evaluation with ethosomal gel

AAPS PharmSciTech

Volumn 13, Issue 4, 2012, Pages 1502-1510

  Patel, Ketul K ^a   Kumar, Praveen ^a   Thakkar, Hetal P ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

ethosomes; lopinavir; niosomes; transdermal

Indexed keywords

CHOLESTEROL; DRUG CARRIER; ETHOSOME; LOPINAVIR; NIOSOME; SORBITAN PALMITATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EX VIVO STUDY; FLUORESCENCE MICROSCOPY; HISTOPATHOLOGY; HYDRATION; HYDROPHILICITY; HYDROPHOBICITY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; SKIN PENETRATION; ZETA POTENTIAL;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; COUMARINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GELS; LIPOSOMES; LOPINAVIR; MALE; PARTICLE SIZE; PERMEABILITY; RATS; RATS, WISTAR; SKIN; SKIN ABSORPTION; SUSPENSIONS;

EID: 84871665048     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9871-7     Document Type: Article

References (23)

1. Ojewole E, Mackraj I, Naidoo P, Govender T. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm. 2008;70(3):697-710.
2. WHO/UNAIDS. UNAIDS report on the global AIDS epidemic. Switzerland; 2010.
3. Abbott L. Clinical Pharmacology and Biopharmaceutics review of Kaletra oral solution (NDA#021251). U.S. Food and Drug Administration (updated 20 November 2001). Available from: http://www.accessdata.fda.gov/drugsatfda-docs/ nda/2000/21-226-Kaletra-biopharmr-P1.pdf. Accessed 23 August 2012
4. ter Heine R, Van Waterschoot RA, Keizer RJ, Beijnen JH, Schinkel AH, Huitema AD. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir. J Pharm Sci. 2011;100(6):2508-15.
5. Attia IA, El-Gizawy SA, Fouda MA, Donia AM. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. AAPS PharmSciTech. 2007;8(4):E106.
6. Balakrishnan P, Shanmugam S, Lee WS, Lee WM, Kim JO, Oh DH, et al. Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm. 2009;377(1-2):1-8.
7. Cable C. An examination of the effects of surface modifications on the physicochemical and biological properties of non-ionic surfactant vesicles. Ph.D. thesis, Glasgow University of Strathclyde; 1989.
8. Jadon PS, Gajbhiye V, Jadon RS, Gajbhiye KR, Ganesh N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS PharmSciTech. 2009;10(4):1186-92.
9. Solanki AB, Parikh JR, Parikh RH, Patel MR. Evaluation of different compositions of niosomes to optimize aceclofenac transdermal delivery. Asian J Pharm Sci. 2010;5(3):87-95.
10. Kushla GP, Zatz JL, Mills Jr OH, Berger RS. Noninvasive assessment of anesthetic activity of topical lidocaine formulations. J Pharm Sci. 1993;82(11):1118-22.
11. Godin B, Touitou E. Ethosomes: new prospects in transdermal delivery. Crit Rev Ther Drug Carrier Syst. 2003;20(1):63-102.
12. Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 2001;228(1-2):43-52.
13. Karki R, Mamatha GC, Subramanya G, Udupa N. Preparation, characterization and tissue disposition of niosomes containing isoniazid. Rasayan J Chem. 2008;1(2):224-7.
14. Verma DD, Verma S, Blume G, Fahr A. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm. 2003;258(1-2):141-51.
15. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release. 2000;65(3):403-18.
16. Bhalaria MK, Naik S, Misra AN. Ethosomes: a novel delivery system for antifungal drugs in the treatment of topical fungal diseases. Indian J Exp Biol. 2009;47(5):368-75.
17. Mokhtar M, Sammour OA, Hammad MA, Megrab NA. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm. 2008;361(1-2):104-11.
18. Manosroi A, Wongtrakul P, Manosroi J, Sakai H, Sugawara F, Yuasa M, et al. Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids Surf B. 2003;30(1):129-38.
19. Essa EA. Effect of formulation and processing variables on the particle size of sorbitan monopalmitate niosomes. Asian J Pharm. 2010;4(4):227-33.
20. Bernsdorff C, Wolf A, Winter R, Gratton E. Effect of hydrostatic pressure on water penetration and rotational dynamics in phospholipid-cholesterol bilayers. Biophys J. 1997;72(3):1264-77.
21. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J. 1980;186(2):591-8.
22. Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Control Release. 2005;106:99-110.
23. Morgan CJ, Renwick AG, Friedmann PS. The role of stratum corneum and dermal microvascular perfusion in penetration and tissue levels of water-soluble drugs investigated by microdialysis. Br J Dermatol. 2003;148(3):434-43.